Ocugen, a US biotech company, said on September 1, 2026 that the first patient had been treated in a large trial of its one-time gene therapy for geographic atrophy, a late form of dry age-related macular degeneration (AMD)1. The company calls it the first pivotal gene therapy trial in geographic atrophy, meaning a trial meant to support an application for approval1. Ocugen says it expects to file for US approval in 20281.
Geographic atrophy affects about 2 to 3 million people in the US and Europe and is a leading cause of permanent loss of central vision in older adults, the company said1. Ocugen expects the number of people with it to rise as the population ages1.
What happened
The trial, called ArMaDa3, is testing a treatment coded OCU4101. It is given once, as a small injection under the retina, the light-sensing layer at the back of the eye1. The treatment uses a modified virus (called AAV5) to carry a human gene called RORA into eye cells1.
The trial plans to enroll 237 people with geographic atrophy caused by dry AMD, at sites in the United States, Canada, Europe and Latin America2. Two out of every three people will get one injection of the gene therapy; the rest will get no treatment, as a comparison group2. The public trial registry describes the study as randomized, with the people who assess the results kept unaware of who got the treatment3. It lists a start date of August 11, 2026 and a main completion date of July 30, 20283.
The main measure is how fast the damaged patches in the eye grow over 12 months, tracked with a type of eye imaging at the start and at months 4, 8 and 122. Secondary measures include how many people lose 15 or more letters on an eye chart read in dim light, at two visits in a row, and how fast a layer of the retina called the ellipsoid zone is lost2.
The evidence so far
The new trial builds on an earlier study called ArMaDa4. Coverage describes its second phase as a randomized, controlled study of 51 people with geographic atrophy4. The registry record, which covers both the first and second phases, lists 60 people enrolled in total5.
According to Ocugen, after 12 months:
- In the medium-dose group, damaged patches grew 31% more slowly than in the untreated group, among people whose patches were in the size range now used for the big trial4. The company called this statistically significant1.
- Loss of the ellipsoid zone layer was 27% lower in the medium-dose group than in the comparison group4.
- About 20% of people in the medium-dose group showed no disease progression, and 75% had growth slowed by more than 30%4.
- No serious side effects linked to the treatment were reported4.
Ocugen described the 31% figure as a potential double benefit compared with the 15% and 22% reductions reported for the treatments already approved in the US, at 12 and 24 months2.
What it does not show yet
The earlier results come from the company and a small number of people. The registry shows that results for the earlier study have not yet been posted5, and none of the sources point to a peer-reviewed publication of the data.
The comparison with approved treatments is the company’s framing. Ocugen’s 31% figure comes from its own trial, while the 15% and 22% figures are those reported for the approved therapies2; the sources do not describe a test of the treatments side by side.
The main measure in the new trial is the growth of damaged patches seen on eye images, not vision itself2. The dim-light eye chart test is included as a secondary measure, described as a link between the image results and how well people see2. Because the comparison group gets no treatment rather than a dummy procedure, patients will know whether they received the injection2. And the trial only follows people for 12 months on its main measure2, which cannot say how long any effect of a one-time treatment would last.
Who is behind it
Ocugen, based in Malvern, Pennsylvania, and listed on Nasdaq, sponsors both trials13. Its chief executive, Shankar Musunuri, said the start of dosing marked “a defining moment” for the program1. He said this is the company’s third gene therapy program of this type to reach late-stage testing1. The others are for retinitis pigmentosa and Stargardt disease, both inherited eye diseases4.
The company’s chief medical officer, Mohamed Genead, described the phase 2 data as “compelling”1. A study investigator, Victor Gonzalez, was quoted in the company’s announcement:
The OCU410 Phase 3 study provides an important opportunity to evaluate a novel, potential one-time gene therapy approach that could lessen the burden of current treatments in the U.S., which require patients to undergo multiple injections every year.
That quote appeared in Ocugen’s own press release1. The sources do not say whether Gonzalez has financial ties to the company.
What regulators have said
On July 29, 2026, the US Food and Drug Administration (FDA) gave the therapy a designation called Regenerative Medicine Advanced Therapy1. It is meant for therapies for serious conditions where early evidence suggests they could meet an unmet need2. It brings more frequent contact with the FDA and makes the therapy eligible for faster review paths, including accelerated approval and priority review4. The designation does not mean the FDA has judged the treatment effective.
Ocugen said that in July 2026 it reached agreement with the FDA on the trial’s design, including its measures, dose and the plan to rely on a single trial to support an application1. In Europe, the European Medicines Agency has classified the therapy as an advanced therapy medicinal product4. Ocugen said talks with the agency are ongoing about whether this one trial could also support a European application1.
How it fits the field
Today, the United States is the only country with approved treatments for geographic atrophy4. Those treatments, known as complement inhibitors, block one disease process and are given as repeated injections into the eye2. Ocugen says geographic atrophy has four main disease drivers, and that the approved treatments address only one of them1.
The company says its therapy is designed to act on all four at once: overactivity of part of the immune system called complement, long-lasting inflammation, oxidative stress (damage from reactive molecules) and problems with how fats are handled1. Whether acting on several processes leads to better results for patients is one of the things the new trial is designed to test.
What to watch next
- Enrollment: how quickly the trial fills its 237 places; the registry lists it as recruiting3.
- Earlier-study data: whether the phase 1/2 results are posted to the registry or published in a journal5.
- Europe: the outcome of Ocugen’s talks with the European Medicines Agency1.
- Timing: main data collection is listed as finishing in July 20283, and Ocugen expects to file with the FDA that year1.
